Objective
STARSTEM proposes imaging of stem cell engraftment in arthritic joints of large animals at clinically relevant depths, using nanoparticles with novel optical properties which enable unprecedented penetration depth and sensitivity. Arthritis is the most prevalent disease worldwide, with osteoarthritis (OA) affecting around 10% of the global population and around 70 million patients in Europe. There is no effective cure for OA at present and the majority of the treatments are symptomatic and not restorative. Stem cell therapy provides a unique opportunity for the self-regeneration of injured cartilage. One of the major hurdles in stem cell mediated-therapy is the inability to diagnose successful engraftment in real time using conventional imaging techniques. STARSTEM will address the major technology gaps to enable imaging of human stem cells at clinically relevant depths. STARSTEM is proposing the use of novel dual plasmonic gold nanostars (nanostars)-enhanced multi-modal imaging to detect stem cell engraftment and tissue repair, and thus their activity and efficacy as a therapy. STARSTEM will harness the best properties of light and sound with a photoacoustic (PA) imaging system for large animal and human finger imaging as proof-of-concept which exploits the unique advantages of our nanomaterial for differential and deep-tissue imaging. Functional imaging using PA enables the real time monitoring of engraftment and the therapeutic process at the site of interest, while highly sensitive anatomical imaging using MRI (using nanostar conjugated with magnetic nanoparticles as contrast agent) enables tracking of the movement and retention in individual organs of the transplanted cells that did not engraft. Algorithms for co-registered PA-MRI imaging approach will enable monitoring of the therapeutic process with high sensitivity. The overall imaging approach is designed to address small to large animal testing for efficacy and safety prior to clinical testing on humans.
Fields of science
- medical and health sciencesclinical medicinerheumatology
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineoncology
- engineering and technologynanotechnologynano-materials
Programme(s)
Topic(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
H91 Galway
Ireland
See on map
Participants (8)
80333 Muenchen
See on map
16126 Genova
See on map
CB2 1TN Cambridge
See on map
08860 Castelldefels
See on map
81379 Munchen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
A94 K542 Blackrock
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
16149 Genova
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
81379 Munchen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.